Hep C Virus - Millennium Biotechnologies, Inc. Announces Placement of Over 750

Millennium Biotechnologies, Inc. Announces Placement of Over 750
Genetic Engineering News - In the past 60 days of Millennium's National product launch in the oncology sector, the Millennium-Cardinal Health partnership has resulted in the successful placement of their innovative Taste & Learning Center (TLC) into over 750 oncology offices

Schering-Plough Drug Gets Fast Track
MSN MoneyCentral - KENILWORTH, N.J. (AP) - Drug maker Schering-Plough Corp. said Monday that regulators granted "fast track" status to its experimental hepatitis C treatment. The Food and Drug Administration gives the fast track label -- which sometimes helps speed the

Viral Hepatitis and HIV Coinfection
Medscape News - In Western countries, chronic HBV infection affects 5% to 10% of HIV-positive individuals. However, a larger proportion of the HIV-infected population has been exposed to HBV in the past. Isolated hepatitis B core antibody (anti-HBc) is more common

Phase II Clinical Trial Shows Vertex's Experimental Protease Inhibitor
Medical News Today - Cambridge, Mass.-based pharmaceutical company Vertex Pharmaceuticals on Tuesday released results of a Phase II clinical trial that showed its experimental drug VX-950 lowered hepatitis C viral loads to undetectable levels, the AP/Houston Chronicle